MiMedx Group, Inc. (NASDAQ:MDXG – Get Rating) CAO William Lawrence Phelan sold 5,750 shares of the stock in a transaction on Friday, May 6th. The stock was sold at an average price of $3.81, for a total value of $21,907.50. Following the completion of the transaction, the chief accounting officer now directly owns 144,640 shares of the company’s stock, valued at approximately $551,078.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
William Lawrence Phelan also recently made the following trade(s):
- On Tuesday, March 8th, William Lawrence Phelan sold 3,268 shares of MiMedx Group stock. The stock was sold at an average price of $4.86, for a total transaction of $15,882.48.
Shares of NASDAQ MDXG opened at $3.46 on Wednesday. MiMedx Group, Inc. has a 1 year low of $3.28 and a 1 year high of $8.69. The firm has a market cap of $392.20 million, a P/E ratio of -20.35 and a beta of 1.92. The stock has a fifty day moving average price of $4.53 and a two-hundred day moving average price of $5.57. The company has a debt-to-equity ratio of 586.91, a quick ratio of 3.24 and a current ratio of 3.71.
Several large investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd bought a new stake in shares of MiMedx Group in the 4th quarter worth approximately $41,000. Spinnaker Investment Group LLC bought a new position in shares of MiMedx Group in the fourth quarter valued at $47,000. Tiedemann Advisors LLC acquired a new stake in shares of MiMedx Group during the 1st quarter valued at $49,000. Barclays PLC bought a new stake in shares of MiMedx Group during the 3rd quarter worth $61,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of MiMedx Group in the 3rd quarter worth $71,000. Institutional investors own 60.31% of the company’s stock.
Separately, StockNews.com started coverage on shares of MiMedx Group in a research note on Thursday, March 31st. They set a “buy” rating on the stock.
MiMedx Group Company Profile (Get Rating)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
- Get a free copy of the StockNews.com research report on MiMedx Group (MDXG)
- Fifth Third Bancorp Stock Bestows Opportunity
- 3 Reasons Why Hostess Brands Could Be a Sweet Addition to Your Watchlist
- XPO Logistics Is A Logical Choice For Investors
- 3 Online Education Stocks Investors Should Study
- If PetMeds Is A Good Buy There Will Be A Better Signal
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.